These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10566048)

  • 1. Azimilide. NE 10064, Stedicor.
    Drugs R D; 1999 Apr; 1(4):297-300. PubMed ID: 10566048
    [No Abstract]   [Full Text] [Related]  

  • 2. Dofetilide. UK 68, UK 68798, Tikosyn, Xelide.
    Drugs R D; 1999 Apr; 1(4):304-11. PubMed ID: 10566050
    [No Abstract]   [Full Text] [Related]  

  • 3. Azimilide dihydrochloride: a new class III anti-arrhythmic agent.
    Abrol R; Page RL
    Expert Opin Investig Drugs; 2000 Nov; 9(11):2705-15. PubMed ID: 11060832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tedisamil. KC 8857.
    Drugs R D; 1999 Apr; 1(4):327-30. PubMed ID: 10566055
    [No Abstract]   [Full Text] [Related]  

  • 5. E 4031.
    Drugs R D; 1999 Apr; 1(4):312-6. PubMed ID: 10566051
    [No Abstract]   [Full Text] [Related]  

  • 6. Azimilide.
    Clemett D; Markham A
    Drugs; 2000 Feb; 59(2):271-7; discussion 278-9. PubMed ID: 10730550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Azimilide: Search for an effective and well-tolerated anti-arrhythmia agent].
    Z Kardiol; 1999 Oct; 88(10 Suppl):1-2. PubMed ID: 10586493
    [No Abstract]   [Full Text] [Related]  

  • 8. Sematilide. CK 1752, CK 1752A, ZK 110516.
    Drugs R D; 1999 Apr; 1(4):322-6. PubMed ID: 10566054
    [No Abstract]   [Full Text] [Related]  

  • 9. Azimilide dihydrochloride: a unique class III antiarrhythmic agent.
    Tran HT
    Heart Dis; 1999; 1(2):114-6. PubMed ID: 11720612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diprafenone.
    Drugs R D; 1999 Apr; 1(4):301-3. PubMed ID: 10566049
    [No Abstract]   [Full Text] [Related]  

  • 11. Landiolol. ONO 1011.
    Drugs R D; 1999 Apr; 1(4):317-8. PubMed ID: 10566052
    [No Abstract]   [Full Text] [Related]  

  • 12. Azimilide dihydrochloride, a novel antiarrhythmic agent.
    Karam R; Marcello S; Brooks RR; Corey AE; Moore A
    Am J Cardiol; 1998 Mar; 81(6A):40D-46D. PubMed ID: 9537222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Otenzepad. AFDX 116.
    Drugs R D; 1999 Apr; 1(4):319-21. PubMed ID: 10566053
    [No Abstract]   [Full Text] [Related]  

  • 14. Newer antiarrhythmic drugs.
    Gupta AK; Maheshwari A; Thakur RK; Lokhandwala YY
    Indian Heart J; 2001; 53(3):354-60. PubMed ID: 11516042
    [No Abstract]   [Full Text] [Related]  

  • 15. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification.
    Camm AJ; Pratt CM; Schwartz PJ; Al-Khalidi HR; Spyt MJ; Holroyde MJ; Karam R; Sonnenblick EH; Brum JM;
    Circulation; 2004 Mar; 109(8):990-6. PubMed ID: 14967728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The class III effect of azimilide is not associated with reverse use-dependence in open-chest dogs.
    Qi XQ; Newman D; Dorian P
    J Cardiovasc Pharmacol; 1999 Dec; 34(6):898-903. PubMed ID: 10598136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of the class III antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia.
    Brooks RR; Carpenter JF; Miller KE; Maynard AE
    Proc Soc Exp Biol Med; 1996 May; 212(1):84-93. PubMed ID: 8618956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction.
    Drexler AP; Micklas JM; Brooks RR
    J Cardiovasc Pharmacol; 1996 Dec; 28(6):848-55. PubMed ID: 8961084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azimilide for atrial fibrillation: clinical trial results and implications.
    Pritchett EL; Marcello SR
    Card Electrophysiol Rev; 2003 Sep; 7(3):215-9. PubMed ID: 14739716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is it rational, reasonable or excessive, and consistently applied? One view of the increasing FDA emphasis on safety first for the release and use of antiarrhythmic drugs for supraventricular arrhythmias.
    Reiffel JA
    J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):333-9. PubMed ID: 11907635
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.